Comparative Pharmacology
Head-to-head clinical analysis: ERAXIS versus MYCAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERAXIS versus MYCAMINE.
ERAXIS vs MYCAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Echinocandin antifungal that inhibits the synthesis of 1,3-beta-D-glucan, an essential component of fungal cell walls, by noncompetitive inhibition of the enzyme 1,3-beta-D-glucan synthase.
Micafungin is an echinocandin antifungal that inhibits the synthesis of 1,3-β-D-glucan, an essential component of the fungal cell wall, leading to osmotic instability and cell death.
50 mg intravenously once daily for invasive candidiasis; 100 mg intravenously once daily for esophageal candidiasis.
100 mg IV once daily for invasive candidiasis; 150 mg IV once daily for esophageal candidiasis.
None Documented
None Documented
Terminal elimination half-life is approximately 50 hours (range 40-70 hours), supporting once-weekly intravenous dosing.
Terminal elimination half-life is approximately 14.3 hours (range 11–17 hours) in healthy adults. In pediatric patients, half-life is shorter (approximately 10–12 hours). Clinically, steady state is achieved by day 3 with daily dosing.
Primarily excreted unchanged in feces (~70%) and urine (~10% as unchanged drug and metabolites). Biliary excretion is the major route for unchanged drug.
Primarily excreted unchanged via feces (approximately 28%) and to a lesser extent via urine (approximately 15%). Overall, elimination is primarily non-renal with biliary/fecal excretion as the major route. Less than 1% is excreted as metabolites.
Category C
Category C
Echinocandin Antifungal
Echinocandin Antifungal